Goldman Sachs
CRMD icon

Goldman Sachs’s CorMedix CRMD Stock Holding History

Goldman Sachs’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,320
Closed -$10K – 6785
2016
Q4 		$10K Sell
1,320
-1,600
-55% -$16.2K ﹤0.01% 6760
2016
Q3 		$37K Buy
2,920
+1,860
+175% +$17.4K ﹤0.01% 6568
2016
Q2 		$11K Buy
1,060
+80
+8% +$1.22K ﹤0.01% 6843
2016
Q1 		$13K Buy
+980
New +$9.51K ﹤0.01% 6845
2015
Q4 		– Sell
-1,900
Closed -$19K – 7170
2015
Q3 		$19K Sell
1,900
-20
-1% -$308 ﹤0.01% 7038
2015
Q2 		$37K Buy
+1,920
New +$65.9K ﹤0.01% 6945

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Oberweis Asset Management
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Goldman Sachs's CRMD Position: Q2 2026 in Review

Goldman Sachs reduced its CorMedix (CRMD) stake by 8.8% in Q2 2026, selling an estimated $355K and leaving 466,393 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4166.

Goldman Sachs first reported a position in CRMD in Q1 2014 and has held it in 34 quarters since. The position peaked at $9.64M in Q4 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Goldman Sachs held 466,393 shares of CorMedix worth $3.66M as of Q2 2026.
  • Goldman Sachs sold 44,936 CorMedix shares in Q2 2026, an estimated $355K.
  • CorMedix made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4166 holding.
  • Goldman Sachs first reported a position in CorMedix in Q1 2014 and has held it in 34 quarters since.
  • Goldman Sachs's CorMedix position peaked at $9.64M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.